Loading…
ClearPoint Neuro, Inc. is projected to rise to $16.71 by 2027, a +45% move from its current price of $11.50. CLPT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.05 | $11.49 | $11.96 | -0.05% |
| May 30 | $10.86 | $11.49 | $12.15 | -0.09% |
| May 31 | $10.72 | $11.48 | $12.30 | -0.14% |
| Jun 1 | $10.61 | $11.48 | $12.42 | -0.18% |
| Jun 2 | $10.50 | $11.47 | $12.53 | -0.23% |
| Jun 3 | $10.41 | $11.47 | $12.64 | -0.28% |
| Jun 4 | $10.32 | $11.46 | $12.73 | -0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.32 | $11.46 | $12.73 | -0.32% |
| Week 2 | $9.85 | $11.43 | $13.25 | -0.64% |
| Week 3 | $9.50 | $11.39 | $13.65 | -0.96% |
| Week 4 | $9.21 | $11.35 | $14.00 | -1.28% |
| Week 5 | $8.95 | $11.32 | $14.30 | -1.60% |
| Week 6 | $8.73 | $11.28 | $14.58 | -1.91% |
| Week 7 | $8.52 | $11.24 | $14.83 | -2.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ClearPoint Neuro, Inc. is a commercial-stage medical device company focused on developing and commercializing platforms for performing minimally invasive surgical procedures in the brain in the United States.
The company offers ClearPoint systems, including ClearPoint hardware (head fixation frame, computer workstation, and in-room monitor), ClearPoint disposables (SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula), and ClearPoint software that guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring. It also provides ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue and the IRRAflow system, an active fluid exchange platform, and consulting services to its pharmaceutical and other medical technology partners.
It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc.
in February 2020. ClearPoint Neuro was incorporated in 1998 and is headquartered in Solana Beach, California.
ClearPoint Neuro, Inc. (CLPT) operates in the Healthcare sector as a medical device company. The stock is currently priced at $11.44 per share and has a market capitalization of $343.08M, with a rank of 3387.
The price outlook is compelling over the longer horizon, as the year-by-year forecast shows a path of growth from 2026 through 2050, with the avg price rising from $11.44 in 2026 to $21.40 in 2030 and ultimately to $90.26 by 2050, including a max of $198.48 in 2050.
Short- to mid-term numbers indicate a neutral-to-bullish transition, with 2026 showing an avg of $11.44 and 0% ROI, then progressively higher averages and strong long-term upside through 2050 (avg $90.26, ROI 689%).
A major floor 24.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 36.3% above — clearing it would confirm fresh momentum.
Key CLPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.53 | Sell | $11.57 | Sell |
| MA 10 | $11.66 | Sell | $11.61 | Sell |
| MA 20 | $11.63 | Sell | $11.51 | Sell |
| MA 50 | $10.62 | Buy | $11.37 | Buy |
| MA 100 | $11.97 | Sell | $12.01 | Sell |
| MA 200 | $14.13 | Sell | $12.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.82 | Neutral |
| Stoch RSI (14) | 15.04 | Buy |
| CCI (20) | -18.11 | Neutral |
| Williams %R (14) | -78.11 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -10.30 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 21.89 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 48.64 | Neutral |
| Momentum (10) | -1.14 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 11.63 | Sell |
| ADX (14) | 10.72 | Neutral |
| ATR (14) | 0.42 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50.
Price action is currently around the SMA50 of $10.59 and below the SMA200 of $14.12, indicating a balance between near-term support and longer-term resistance.
Key levels to watch are support at $10.01 and resistance at $12.82. The 30-day range trades between $8.73 and $15.00, highlighting recent consolidation within a roughly $6 range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.66 | $11.50 | $17.26 | 0% | Neutral | |
| $12.68 | $16.71 | $23.64 | +45% | Bullish | |
| $13.86 | $19.04 | $28.27 | +66% | Bullish | |
| $14.24 | $20.27 | $31.26 | +76% | Bullish | |
| $14.71 | $21.60 | $34.39 | +88% | Bullish | |
| $13.16 | $19.91 | $32.58 | +73% | Bullish | |
| $14.07 | $21.87 | $36.70 | +90% | Bullish | |
| $18.12 | $28.90 | $49.58 | +151% | Bullish | |
| $19.61 | $32.07 | $56.16 | +179% | Bullish | |
| $21.28 | $35.67 | $63.65 | +210% | Bullish | |
| $24.57 | $46.09 | $88.97 | +301% | Bullish | |
| $40.45 | $89.88 | $194.14 | +682% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.66 | $11.50 | $13.61 | +0.00% |
| June 2026 | $9.58 | $11.36 | $13.88 | -1.19% |
| July 2026 | $9.18 | $11.03 | $13.73 | -2.95% |
| August 2026 | $9.62 | $11.66 | $14.73 | +5.71% |
| September 2026 | $10.11 | $12.35 | $15.79 | +5.98% |
| October 2026 | $9.93 | $12.23 | $15.80 | -1.01% |
| November 2026 | $9.95 | $12.33 | $16.08 | +0.83% |
| December 2026 | $10.52 | $13.12 | $17.26 | +6.41% |
Click any year to see its month-by-month CLPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CLPT could reach as high as $17.26, with a base case around $11.50 and support toward $8.66 — roughly 0% from $11.50. Price action looks broadly range-bound.
Expect CLPT to range from $12.68 to $23.64 through 2027. The $16.71 average target implies a +45% move from current prices. That is up +45% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CLPT price prediction for 2028 points to an average of $19.04 (low $13.86, high $28.27) — a potential gain of +66% on today's $11.50. Momentum favours further upside here.
In 2029, CLPT is projected to trade between $14.24 and $31.26, averaging $20.27 — a potential gain of +76% from today's $11.50. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
ClearPoint Neuro, Inc.'s 2030 outlook centres on $21.60, within a $14.71 to $34.39 range. That is up +7% on the projected 2029 average. That marks a +88% change versus current levels. Momentum favours further upside here.
By 2031, CLPT could reach as high as $32.58, with a base case around $19.91 and support toward $13.16 — roughly +73% from $11.50. Buyers look set to stay in control over this stretch.
Expect CLPT to range from $14.07 to $36.70 through 2032. The $21.87 average target implies a +90% move from current prices. That is up +10% on the projected 2031 average. Momentum favours further upside here.
The CLPT price prediction for 2033 points to an average of $28.90 (low $18.12, high $49.58) — a potential gain of +151% on today's $11.50. Buyers look set to stay in control over this stretch.
In 2034, CLPT is projected to trade between $19.61 and $56.16, averaging $32.07 — a potential gain of +179% from today's $11.50. That is up +11% on the projected 2033 average. Momentum favours further upside here.
ClearPoint Neuro, Inc.'s 2035 outlook centres on $35.67, within a $21.28 to $63.65 range. That is up +11% on the projected 2034 average. That marks a +210% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CLPT could reach as high as $88.97, with a base case around $46.09 and support toward $24.57 — roughly +301% from $11.50. Momentum favours further upside here.
Expect CLPT to range from $40.45 to $194.14 through 2050. The $89.88 average target implies a +682% move from current prices. That is up +95% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLPT today (≈ 86.956522 CLPT) could be worth
$7,815.67
+$6,815.67 (+682%) by 2050 · US Dollar
Based on the average projected CLPT price of $89.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLPTwould be worth at today's price.
$1,000 invested in CLPT on May 27, 2025 (≈ 79.744817 CLPT) would be worth
$917.07
-$82.93 (-8.3%) today · 0.92× · US Dollar
Based on a CLPT entry price of $12.54 vs. today's $11.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.2 | $1,026.79 | +2.7% |
| 1 month ago | $11.21 | $1,025.87 | +2.6% |
| 3 months ago | $14.43 | $796.95 | -20.3% |
| 6 months ago | $14.46 | $795.3 | -20.5% |
| 1 year ago | $12.54 | $917.07 | -8.3% |
| All time (5.0y) ago | $18.46 | $622.97 | -37.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLPT forecast.
Our base-case forecast reaches $23.00 around 2033.
Implied market cap at $23.00: $689.76M
The multi-year forecast shows a clear bullish trajectory beyond 2026. The 2026 average is $11.44, with 2027 average $16.64 and 2028 average $19.26, and a 2029 average of $20.45, before reaching $21.40 in 2030 (ROI 87.1). The sentiment for 2027 and beyond is BULLISH, following a Neutral 2026 with 0% ROI.
From 2031 onward the forecast remains positive, with 2031 average $19.90 and 2032 $21.95, then 2033 $28.93 (ROI 152.9), 2034 $32.35 (ROI 182.8), and 2035 $35.92 (ROI 213.9). By 2040, the average is $46.59 (ROI 307.2). In 2050, the average reaches $90.26 with a max of $198.48 and ROI of 689 (sentiment BULLISH).
These figures illustrate substantial upside potential over the long term, though they are estimates and not guarantees. Caution is warranted given the near-term neutral outlook in 2026 and the inherent uncertainties in market and clinical adoption dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows min $14.41, avg $21.40, max $34.45, with ROI 87.1 and sentiment BULLISH.
The long-term forecast is bullish, with avg rising to $90.26 by 2050 and ROI 689%, though 2026 is Neutral with ROI 0%. These are estimates, not guarantees.
Yes—the 2050 forecast max is $198.48, which exceeds $100, indicating potential upside in the long term, but not a guarantee.
Current price is $11.44 per share and the market capitalization is $343.08M.
The 30-day range is $8.73 to $15.00. The SMA50 is $10.59 and the SMA200 is $14.12; RSI14 is 50 and sentiment is NEUTRAL.
ClearPoint Neuro, Inc. Community Discussion
0Share your ClearPoint Neuro, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.